S
SRPT icon

Seeyond’s Sarepta Therapeutics SRPT Stock Holding History

Seeyond’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,812
Closed -$140K – 611
2021
Q2 		$140K Buy
1,812
+8
+0.4% +$607 0.01% 565
2021
Q1 		$134K Sell
1,804
-24,752
-93% -$2.28M 0.01% 575
2020
Q4 		$4.53M Sell
26,556
-1,302
-5% -$193K 0.47% 29
2020
Q3 		$3.91M Buy
27,858
+2,913
+12% +$443K 0.42% 37
2020
Q2 		$4M Buy
24,945
+2,117
+9% +$288K 0.45% 33
2020
Q1 		$651K Buy
22,828
+21,338
+1,432% +$2.44M 0.09% 318
2019
Q4 		$192K Hold
1,490
– – 0.02% 552
2019
Q3 		$112K Buy
+1,490
New +$176K 0.01% 578

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Seeyond's SRPT Position: Q3 2021 in Review

Seeyond sold out of Sarepta Therapeutics (SRPT) in Q3 2021, closing a stake of 1,812 shares — an estimated $140K sold.

Seeyond first reported a position in SRPT in Q3 2019 and held it in 8 quarters. The position peaked at $4.53M in Q4 2020. 306 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

  • Seeyond reported no remaining Sarepta Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Seeyond sold 1,812 Sarepta Therapeutics shares in Q3 2021, an estimated $140K.
  • Seeyond first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 8 quarters.
  • Seeyond's Sarepta Therapeutics position peaked at $4.53M in Q4 2020.
  • 306 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Seeyond's 13F filing for Q3 2021, filed 12 Nov 2021.